ESMO: Daiichi's HER3-Targeting ADC Shows Promise, Particularly In Resistant Tumors

Potential First-In-Class Agent

 
• By John Davis
Arrows
Targeting HER3 May Be A Winning Strategy • Source: Shutterstock

More from Clinical Trials

More from R&D